Search

Adler, CH, RA Hauser, K Sethi, JN Caviness, L Marlor, M Anderson, and JG Hentz. 2004. “Ropinirole for Restless Legs Syndrome: A Placebo-Controlled Crossover Trial. Neurology 2004;62:1405-1407.”. Neurology.

Crawford, FC, G Ait-Ghezala, M Morris, MJ Sutcliffe, RA Hauser, AA Silver, and MJ Mullan. 2003. “Translocation Breakpoint in Two Unrelated Tourette Syndrome Cases, Within a Region Previously Linked to the Disorder. Hum Genet 2003;113:154-161.”. Hum Genet.

Zesiewicz, TA, S Borra, and RA Hauser. 2002. “Clozapine Withdrawal Symptoms in a Parkinson’s Disease Patient. Movement Disorders 2002;17:1365-1367.”. Movement Disorders.

Sahiner, Mehtap, Aynur S. Yilmaz, Ramesh S. Ayyala, and Nurettin Sahiner. 2023. “Carboxymethyl Chitosan Microgels for Sustained Delivery of Vancomycin and Long-Lasting Antibacterial Effects”. Gels 9 (9).

Can, Mehmet ", Ramesh S Ayyala, and Nurettin" Sahiner. 2019. “Crosslinked Poly(Lactose) Microgels and Nanogels for Biomedical Applications”. J. Colloid Interface Sci. 553: 805-12.

Suner, Selin S ", Sahin Demirci, Berkant and Yetiskin, Rawil Fakhrullin, Ekaterina Naumenko, Oguz Okay, Ramesh S Ayyala, and Nurettin " Sahiner. 2019. “Cryogel Composites Based on Hyaluronic Acid and Halloysite Nanotubes As Scaffold for Tissue Engineering”. Int. J. Biol. Macromol. 130: 627-35.

Ayyala, Ramesh S, Jessica Laursen Duarte, and . 2006. “Glaucoma Drainage Devices: State of the Art”. Expert Rev. Med. Devices 3 (4): 509-21.

Weiner, WJ, SA Factor, J Jankovic, RA Hauser, JW Tetrud, CH Waters, LM Shulman, and . 2001. “The Long-Term Safety and Efficacy of Pramipexole in Advanced Parkinson’s Disease. Parkinsonism and Related Disorders 2001;7(2)115-120.”. Parkinsonism and Related Disorders.

Hauser, RA, J Friedlander, MJ Baker, J Thomas, and R Zuckerman. 2000. “Adult Chediak-Higashi Parkinsonian Syndrome With Dystonia. Movement Disorders 2000;15:705-708.”. Movement Disorders.

Freeman, TB, RA Hauser, AE Willing, T Zigova, PR Sanberg, and S Saporta. 2000. “Transplantation of Human Fetal Striatal Tissue in Huntington’s Disease: Rationale for Clinical Studies. Novartis Foundation Symposium 2000;231:129-138; Discussion 139-147.”. Novartis Foundation Symposium.